 | Up a level |
Dreyling, Martin; Doorduijn, Jeanette; Giné, Eva; Jerkeman, Mats; Walewski, Jan; Hutchings, Martin; Mey, Ulrich; Riise, Jon; Trneny, Marek; Vergote, Vibeke; Shpilberg, Ofer; Gomes da Silva, Maria; Leppä, Sirpa; Jiang, Linmiao; Stilgenbauer, Stephan; Kerkhoff, Andrea; Jachimowicz, Ron D; Celli, Melania; Hess, Georg; Arcaini, Luca; ... (2024). Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. (In Press). The lancet Elsevier 10.1016/S0140-6736(24)00184-3
Morris, Curly; de Wreede, Liesbeth; Scholten, Marijke; Brand, Ronald; van Biezen, Anja; Sureda, Anna; Dickmeiss, Ebbe; Trneny, Marek; Apperley, Jane; Chiusolo, Patrizia; van Imhoff, Gustaaf W; Lenhoff, Stig; Martinelli, Giovanni; Hentrich, Marcus; Pabst, Thomas; Onida, Francesco; Quinn, Michael; Kroger, Nicolaus; de Witte, Theo and Ruutu, Tapani (2014). Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide. Transfusion, 54(10), pp. 2514-2522. Wiley-Blackwell 10.1111/trf.12759
